Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2017 Earnings Results

Madrigal Pharmaceuticals Misses on EPS, Stock Up 1.25%

Madrigal Pharmaceuticals reported a loss per share of $0.68, which was in line with expectations, but no revenue figures were disclosed. The stock rose by 1.25%, indicating that investors may be responding positively to management's commentary on clinical progress and future potential. The lack of guidance suggests uncertainty about short-term performance, but the overall tone was optimistic.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.68	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their pipeline. They acknowledged the challenges but are optimistic about upcoming milestones.

Management highlighted ongoing progress in clinical trials.

They expressed confidence in future developments despite current losses.

Madrigal Pharmaceuticals Misses on EPS, Stock Up 1.25%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS, Stock Up 1.25%

Key numbers

Management commentary